Quinupristin/dalfopristin

Revision as of 15:13, 15 January 2016 by NicoleZadzilka (talk | contribs) (Created page with "==Uses== * Treatment of vancomycin-resistant Enterococcus faecium, as well as nosocomial pneumonias and infections secondary to IV catheters (1) ==Administration== *Dosage Fo...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Uses

  • Treatment of vancomycin-resistant Enterococcus faecium, as well as nosocomial pneumonias and infections secondary to IV catheters (1)

Administration

  • Dosage Forms: 500 mg vials, diluted into 250 mL and given over 60 mins
  • Routes of Administration: IV
  • Common Trade Names: Synercid

Adult Dosing

  • VRE: 7.5 mg/kg IV q8 hrs for minimum 7 days
  • skin infections: 7.5 mg/kg IV q12 hrs for minimum 7 days

Pediatric Dosing

  • safety and efficacy has not been studied in children

Special Populations

  • Pregnancy Rating: B
  • Lactation risk: unknown whether secreted in human breast milk. Caution should be exercised when administering to nursing mothers. (2)

Renal Dosing

  • no adjustments for renal impairment

Hepatic Dosing

  • dosage may need to be adjusted in patients with cirrhosis, however specific dose modification is not known at this time (2)


Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

Common

  • pain and inflammation at infusion site
  • arthralgias
  • nausea/vomiting/diarrhea
  • rash
  • headache
  • pruritis

Pharmacology

  • Half-life: Quinupristin: 3 hrs; Dalfopristin: 1 hr
  • Metabolism: significantly interacts with the CYP 3A4 system.
  • Excretion:


References